Debu Tripathy, MD, discusses updated results of the phase 3 MONALEESA-7 trial in hormone receptor–positive, HER2-negative breast cancer.
Debu Tripathy, MD, professor of medicine and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses updated results of the phase 3 MONALEESA-7 trial (NCT02278120) in hormone receptor (HR)–positive, HER2-negative breast cancer.
The MONALEESA-7 trial randomized patients to receive ribociclib (Kisqali) or placebo in combination with goserelin plus a nonsteroidal aromatase inhibitor or tamoxifen.
Updated findings from the study, which were presented virtually during the 2020 San Antonio Breast Cancer Symposium, showed that with an extended follow up of 53.5 months, the overall survival was 58.7 months with ribociclib plus endocrine therapy compared with 48.0 months with placebo plus endocrine therapy (HR, 0.763; 95% CI, 0.608-0.956), Tripathy says.
This translates to about a 24% reduction in the risk of death with ribociclib, concludes Tripathy.